The potential application of iron chelators for the treatment of neurodegenerative diseases

Metallomics ◽  
2011 ◽  
Vol 3 (3) ◽  
pp. 239 ◽  
Author(s):  
Robert C. Hider ◽  
Sourav Roy ◽  
Yong Min Ma ◽  
Xiao Le Kong ◽  
Jane Preston
Keyword(s):  
Neurodegenerative Diseases ◽  
Potential Application ◽  
Iron Chelators

Multifunctional iron-chelators with protective roles against neurodegenerative diseases

2013 ◽  
Vol 42 (17) ◽  
pp. 6058 ◽  
Author(s):  
Andreia Nunes ◽  
Sérgio M. Marques ◽  
Catarina Quintanova ◽  
Diana F. Silva ◽  
Sandra M. Cardoso ◽  
...  
Keyword(s):  
Neurodegenerative Diseases ◽  
Iron Chelators

scholarly journals Neuroprotective Effect of Several Phytochemicals and Its Potential Application in the Prevention of Neurodegenerative Diseases

Geriatrics ◽  
2016 ◽  
Vol 1 (4) ◽  
pp. 29 ◽  
Author(s):  
Jintang Wang ◽  
Yuetao Song ◽  
Maolong Gao ◽  
Xujing Bai ◽  
Zheng Chen
Keyword(s):  
Neurodegenerative Diseases ◽  
Potential Application ◽  
Neuroprotective Effect

Flavopiridol: an antitumor drug with potential application in the treatment of neurodegenerative diseases

2005 ◽  
Vol 64 (1) ◽  
pp. 120-123 ◽  
Author(s):  
M. Pallàs ◽  
E. Verdaguer ◽  
E.G. Jordà ◽  
A. Jiménez ◽  
A.M. Canudas ◽  
...  
Keyword(s):  
Neurodegenerative Diseases ◽  
Potential Application ◽  
Antitumor Drug

In silico strategies for the selection of chelating compounds with potential application in metal-promoted neurodegenerative diseases

2010 ◽  
Vol 25 (1) ◽  
pp. 21-30 ◽  
Author(s):  
Cristina Rodríguez-Rodríguez ◽  
Albert Rimola ◽  
Jorge Alí-Torres ◽  
Mariona Sodupe ◽  
Pilar González-Duarte
Keyword(s):  
Neurodegenerative Diseases ◽  
In Silico ◽  
Potential Application ◽  
Chelating Compounds ◽  
Selection Of

scholarly journals Phytocannabinoids: General Aspects and Pharmacological Potential in Neurodegenerative Diseases

2020 ◽  
Vol 18 ◽  
Author(s):  
Graziella dos Reis Franco ◽  
Scott Smid ◽  
Cláudio Viegas
Keyword(s):  
Drug Development ◽  
Neurodegenerative Diseases ◽  
Disease Progression ◽  
Potential Application ◽  
Neurological Diseases ◽  
Drug Candidates ◽  
Disease Modifying ◽  
Pharmacological Potential ◽  
General Aspects ◽  
State Of Art

: In the last few years research into Cannabis and its constituent phytocannabinoids has burgeoned, particularly in the potential application of novel cannabis phytochemicals for the treatment of diverse illnesses related to neurodegeneration and dementia, including Alzheimer's (AD), Parkinson's (PD) and Huntington's disease (HD). To date, these neurological diseases have mostly relied on symptomatological management. However, with an aging population globally, the search for more efficient and disease-modifying treatments that could delay or mitigate disease progression is imperative. In this context, this review aims to present a state of art in the research with cannabinoids and novel cannabinoid-based drug candidates that have been emerged as novel promising alternatives for drug development and innovation in the therapeutics of a number of diseases, especially those related to CNS-disturbance and impairment.

Promotion of the Differentiation of Dental Pulp Stem Cells into Oligodendrocytes by Knockdown of Heat-Shock Protein 27

2022 ◽  
Author(s):  
Shu-Lin Guo ◽  
Chih-Hui Chin ◽  
Chi-Jung Huang ◽  
Chih-Cheng Chien ◽  
Yih-Jing Lee
Keyword(s):  
Stem Cells ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Neurodegenerative Diseases ◽  
Dental Pulp ◽  
Potential Application ◽  
Neural Differentiation ◽  
Heat Shock Protein 27 ◽  
Dental Pulp Stem Cells ◽  
Immunofluorescent Staining

Stem cell-based therapy has been evaluated in many different clinical trials for various diseases. This capability was applied in various neurodegenerative diseases, such as Alzheimer’s disease, which is characterized by synaptic damage accompanied by neuronal loss. Dental pulp stem cells (DPSCs) are mesenchymal stem cells from the oral cavity and have been studied with potential application for regeneration of different tissues. Heat shock protein 27 (HSP27) is known to regulate neurogenesis in the process of neural differentiation of placenta-multipotent stem cells. Here, we hypothesize that HSP27 expression is also critical in neural differentiation of DPSCs. An evaluation of the possible role of HSP27 in differentiation of DPSCs was per-formed by gene knockdown and neural immunofluorescent staining. We found that HSP27 has a role in the differentiation of DPSCs and that knockdown of HSP27 in DPSCs renders cells to oligodendrocyte progenitors. In other words, shHSP27-DPSCs showed NG2-positive immunoreactivity and gave rise to oligodendrocytes or type-2 astrocytes. This neural differentiation of DPSCs may have clinical significance for treatment of patients with neurodegenerative diseases. In conclusion, our data provide an example of oligodendrocyte differentiation of a DPSCs model that may have potential application in human regenerative medicine.

scholarly journals New Perspectives in Iron Chelation Therapy for the Treatment of Neurodegenerative Diseases

2018 ◽  
Vol 11 (4) ◽  
pp. 109 ◽  
Author(s):  
Marco Nuñez ◽  
Pedro Chana-Cuevas
Keyword(s):  
Clinical Trials ◽  
Neurodegenerative Diseases ◽  
Iron Homeostasis ◽  
Chelation Therapy ◽  
Iron Chelation ◽  
Species Interaction ◽  
Iron Chelators ◽  
Iron Chelation Therapy ◽  
Therapeutic Concept ◽  
Long Term Treatment

Iron chelation has been introduced as a new therapeutic concept for the treatment of neurodegenerative diseases with features of iron overload. At difference with iron chelators used in systemic diseases, effective chelators for the treatment of neurodegenerative diseases must cross the blood–brain barrier. Given the promissory but still inconclusive results obtained in clinical trials of iron chelation therapy, it is reasonable to postulate that new compounds with properties that extend beyond chelation should significantly improve these results. Desirable properties of a new generation of chelators include mitochondrial destination, the center of iron-reactive oxygen species interaction, and the ability to quench free radicals produced by the Fenton reaction. In addition, these chelators should have moderate iron binding affinity, sufficient to chelate excessive increments of the labile iron pool, estimated in the micromolar range, but not high enough to disrupt physiological iron homeostasis. Moreover, candidate chelators should have selectivity for the targeted neuronal type, to lessen unwanted secondary effects during long-term treatment. Here, on the basis of a number of clinical trials, we discuss critically the current situation of iron chelation therapy for the treatment of neurodegenerative diseases with an iron accumulation component. The list includes Parkinson’s disease, Friedreich’s ataxia, pantothenate kinase-associated neurodegeneration, Huntington disease and Alzheimer’s disease. We also review the upsurge of new multifunctional iron chelators that in the future may replace the conventional types as therapeutic agents for the treatment of neurodegenerative diseases.

Sign in / Sign up

Export Citation Format

Share Document